Last reviewed · How we verify
[14C] radiolabelled GSK2190915 solution — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
[14C] radiolabelled GSK2190915 solution ([14C] radiolabelled GSK2190915 solution) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| [14C] radiolabelled GSK2190915 solution TARGET | [14C] radiolabelled GSK2190915 solution | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- [14C] radiolabelled GSK2190915 solution CI watch — RSS
- [14C] radiolabelled GSK2190915 solution CI watch — Atom
- [14C] radiolabelled GSK2190915 solution CI watch — JSON
- [14C] radiolabelled GSK2190915 solution alone — RSS
Cite this brief
Drug Landscape (2026). [14C] radiolabelled GSK2190915 solution — Competitive Intelligence Brief. https://druglandscape.com/ci/14c-radiolabelled-gsk2190915-solution. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab